Evaluation of dosing and clinical response to darbepoetin alfa (DA) and epoetin alfa (EPO) in patients treated for chemotherapy-induced anemia in hospital oncology outpatient clinics.

被引：0
作者：
Gupta, V
Rago, MA
Goetz, A
Fastenau, J
Watson, S
机构：
[1] Cardinal Hlth Clin Serv & Consulting, Pharmaceut & Clin Informat Serv, Houston, TX USA
[2] Ortho Biotech, Clin Affairs, Bridgewater, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5768
引用
收藏
页码：509B / 509B
页数：1
相关论文
共 50 条
[21]   Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies [J].
Case, Ashley S. ;
Rocconi, Rodney P. ;
Kilgore, Larry C. ;
Barnes, Mack N. .
GYNECOLOGIC ONCOLOGY, 2006, 101 (03) :499-502
[22]   COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL OUTPATIENT SETTING [J].
Vekeman, Francis ;
McKenzie, R. Scott ;
Lafeuille, Marie-Helene ;
Bailey, Robert A. ;
Piech, Catherine Tak ;
Lefebvre, Patrick .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) :A78-A78
[23]   CHEMOTHERAPY-INDUCED ANEMIA MANAGEMENT WITH DARBEPOETIN ALFA IN DAILY CLINICAL PRACTICE [J].
Cruz, M. A. ;
Bustos, A. ;
Carabantes, F. ;
Diaz, N. ;
Rovira, P. Sanchez ;
Froilan, J. ;
Lorenzo, I. ;
Gasquet, J. A. ;
Alegre, A. .
ANNALS OF ONCOLOGY, 2008, 19 :284-284
[24]   Darbepoetin alfa for the treatment of chemotherapy-induced anemia in patients with solid tumors [J].
Bustos, A. ;
Carabantes, F. ;
Alvarez, R. ;
Diaz, N. ;
Bueso, P. ;
Lazaro, M. ;
Gasquet, J. A. ;
Alegre, A. .
EJC SUPPLEMENTS, 2009, 7 (02) :197-197
[25]   Evaluation of extended dosing intervals versus weekly dosing of darbepoetin alfa (DA): A phase 2 study in cancer patients (pts) with chemotherapy-induced anemia (CIA) [J].
Rearden, T. ;
Schwartzberg, L. ;
Mirtsching, B. ;
Tomita, D. ;
Lillie, T. ;
Burkes, R. ;
Silberstein, P. .
EJC SUPPLEMENTS, 2007, 5 (04) :154-154
[26]   COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL INPATIENT AND OUTPATIENT SETTING [J].
Lafeuille, Marie-Helene ;
Bailey, Robert A. ;
Senbetta, Mekre ;
Lefebvre, Patrick .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) :A56-A56
[27]   Anemia Management With Darbepoetin-Alfa in Outpatient Hemodialysis Patients Switched From Epoetin-Alfa: A Community Hospital Experience [J].
Agrawal, Varun ;
Mukherjee, Sudipto ;
Kosuri, Rajani ;
Dumler, Francis .
AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (05) :469-475
[28]   ARTIST: Evaluation of the current management of hemoglobin (Hb) levels in cancer patients with symptomatic chemotherapy-induced anemia (CIA) treated with darbepoetin alfa (DA) [J].
Smakal, M. ;
Ruzsa, A. ;
Hemetsberger, M. ;
Kurhanska, A. ;
Ianakieva, V. ;
Niepel, D. .
EUROPEAN JOURNAL OF CANCER, 2018, 92 :S51-S52
[29]   Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: A retrospective cohort study [J].
Nurko, Saul ;
Spirko, Rita ;
Law, Amy ;
Dennis, Vincent W. .
CLINICAL THERAPEUTICS, 2007, 29 (09) :2010-2021
[30]   Hematologic outcomes and costs in epoetin alfa (EPO) and darbepoetin alfa (DARB) treated cancer patients with anemia: results of the Dosing and Outcomes Study of Erythropoiesis Stimulating Therapies (DOSE Registry). [J].
Memisoglu, A ;
Peake, C ;
Vichare, R ;
McKenzie, RS ;
Howell, J ;
Piech, CT .
PHARMACOTHERAPY, 2005, 25 (10) :1469-1469
12345